The newly formed International Serious Adverse Events Consortium (SAEC) plans to launch 2 initial research programs designed to identify genetic markers that may help predict which individuals are at risk for serious drug-related adverse events.
The studies will address drug-related liver toxicity and the rare but serious drug-related skin condition Stevens-Johnson syndrome. Patients respond differently to medicines, and all medicines can have side effects in some individuals.
The SAEC's work is based on the hypothesis that these differences have a genetic basis, and its research studies will examine the impact genes can have on how individuals respond to drugs. The findings will be made available to the research community for further study. The groups' objectives are as follows:
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs